Skip to main content

Table 4 Incremental cost per QALY gained

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Treatments ordered from least to most effective

Patient-level

Population-level (100 MDR patients)

Incremental cost per QALY gained (€)

Total cost, €

Total QALYs gained

Total LYG

Total cost, €

Total QALYs gained

Total LYG

Versus BR alone

Versus Linezolid plus BR

Versus delamanid plus BR

BR alone

60,962

3.68

4.82

6,096,152

368

482

87,484

38,703

Linezolid plus BR

80,460

3.91

5.07

8,045,981

391

507

87,484

2026

Delamanid plus BR

81,079

4.21

5.36

8,107,888

421

536

38,703

2026

Bedaquiline plus BR

85,575

4.79

5.95

8,557,529

479

595

22,238

5787

7774

  1. BR Background Regimen, QALY Quality-Adjusted Life Year, LYG life-years gained